AstraZeneca reports positive late-stage results for two lung cancer therapies
AstraZeneca announced successful outcomes from two late-stage trials targeting distinct forms of lung cancer. One trial tested a combination of Tagrisso and Orpathys, while the other evaluated the antibody-drug conjugate Enhertu. The results bolster the company's oncology pipeline and could expand treatment options.
Related stories
Biokin's EGFRxHER3 ADC succeeds in Chinese lung cancer trial, boosting BMS global hopes · Cancer research
Zipalertinib succeeds in Phase 3 trial for EGFR-mutant lung cancer, challenging Rybrevant · Cancer research
AstraZeneca halts late-stage lung cancer trial; U.S. drug prices decline · Cancer research
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “AstraZeneca touts separate late-stage lung cancer wins with Tagrisso, Enhertu.” Browse more stories.